Efferent Labs is a preclinical stage medical technology company focused on implantable biosensors. Our CytoComm™ Biosensor Platform is designed to serve as a real-time monitoring system, using living cells to assess cellular function in vivo. Our system is built to transmit live data through the cloud to our data acquisition and analysis software, providing real-time information to researchers and clinicians.

The CytoComm™ Biosensor Platform has multiple applications including preclinical R&D, clinical testing, oncology, cardiology, and metabolic diseases.

“Living cells can tell us more about life processes than any instrument can.”

Preclinical

CytoComm™ is designed to allow researchers to gather multiple data points from the same animal for the duration of a study, resulting in a significant decrease in the number of animals required.

Oncology

CytoComm™ is designed to allow doctors to tailor a course of chemotherapy to the patient, eliminating the dramatic swings in the administration of medication.

Cardiology

CytoComm™ is designed to provide real-time monitoring in at-risk cardiac patients, measuring levels of precursors and other markers within the patient.

 

 

Benefits

Real-time feedback of cellular function

 

Living cell lines provide a powerful tool to assess cellular function in vivo.

 

Read More

chart21

More data, more often

CytoComm™ is being designed as a platform that wirelessly gathers targeted real-time data for analysis by researchers and physicians.

 

Read More

 

Updates

 

 

Recent Press

Efferent Labs Taps Evotec to Advance Implantable Biosensor for R&D, Oncology

January 18, 2017

FierceBiotech Efferent Labs has inked a deal with Evotec to develop its implantable biosensor technology. The device, which is injected...

Read more

Efferent Labs Signs Agreement With Evotec AG To Continue Development Of Groundbreaking Medical Diagnostic Product

January 9, 2017

January 9, 2017 FOR MORE INFORMATION CONTACT:  press@efferentlabs.com Download the Press Release

Read more